Redx Pharma Past Earnings Performance
Past criteria checks 0/6
Redx Pharma's earnings have been declining at an average annual rate of -34.4%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 38% per year.
Key information
-34.4%
Earnings growth rate
-13.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 38.0% |
| Return on equity | -988.3% |
| Net Margin | -789.1% |
| Last Earnings Update | 30 Sep 2023 |
Revenue & Expenses BreakdownBeta
How Redx Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 4 | -33 | 8 | 29 |
| 30 Jun 23 | 8 | -31 | 9 | 30 |
| 31 Mar 23 | 13 | -29 | 10 | 32 |
| 31 Dec 22 | 16 | -24 | 10 | 30 |
| 30 Sep 22 | 19 | -18 | 10 | 29 |
| 30 Jun 22 | 17 | -18 | 9 | 28 |
| 31 Mar 22 | 16 | -19 | 8 | 27 |
| 31 Dec 21 | 13 | -20 | 7 | 26 |
| 30 Sep 21 | 10 | -22 | 6 | 24 |
| 30 Jun 21 | 8 | -20 | 7 | 23 |
| 31 Mar 21 | 7 | -18 | 8 | 21 |
| 31 Dec 20 | 6 | -14 | 6 | 16 |
| 30 Sep 20 | 6 | -9 | 4 | 10 |
| 30 Jun 20 | 5 | -8 | 13 | 0 |
| 31 Mar 20 | 4 | -6 | 10 | 0 |
| 31 Dec 19 | 4 | -5 | 10 | 0 |
| 30 Sep 19 | 3 | -4 | 10 | 0 |
| 30 Jun 19 | 2 | -5 | 10 | 0 |
| 31 Mar 19 | 0 | -7 | 11 | 0 |
| 31 Dec 18 | 0 | -8 | 11 | 0 |
| 30 Sep 18 | 0 | -9 | 11 | 0 |
| 30 Jun 18 | 15 | -1 | 8 | 0 |
| 31 Mar 18 | 31 | 8 | 5 | 0 |
| 31 Dec 17 | 31 | 5 | 5 | 0 |
| 30 Sep 17 | 30 | 2 | 5 | 0 |
| 30 Jun 17 | 15 | -9 | -1 | 0 |
| 31 Mar 17 | 0 | -19 | -7 | 0 |
| 31 Dec 16 | 0 | -17 | -3 | 0 |
| 30 Sep 16 | 0 | -16 | 1 | 0 |
| 30 Jun 16 | 0 | -14 | 8 | 0 |
| 31 Mar 16 | 0 | -12 | 14 | 0 |
| 31 Dec 15 | 0 | -10 | 13 | 0 |
| 30 Sep 15 | 0 | -8 | 12 | 0 |
| 30 Jun 15 | 0 | -7 | 11 | 0 |
| 31 Mar 15 | 0 | -5 | 11 | 0 |
| 31 Dec 14 | 0 | -4 | 11 | 0 |
| 30 Sep 14 | 0 | -3 | 10 | 0 |
Quality Earnings: REDX is currently unprofitable.
Growing Profit Margin: REDX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: REDX is unprofitable, and losses have increased over the past 5 years at a rate of 34.4% per year.
Accelerating Growth: Unable to compare REDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: REDX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: REDX has a negative Return on Equity (-988.26%), as it is currently unprofitable.